medigraphic.com
ISSN 0188-2198 (Impreso)

1999, Número 1

Siguiente >>

Rev Mex Cardiol 1999; 10 (1)


Consenso Mexicano de Resistencia a la Insulina y Síndrome Metabólico

González CA

Idioma: Español
Referencias bibliográficas: 108
Paginas: 3-19
Archivo PDF: 182.27 Kb.


FRAGMENTO

El concepto de resistencia a la insulina fue descrito por Himsworth desde hace más de 60 años; ya desde esa época se consideró su posible participación etiopatogénica en el curso clínico de las enfermedades metabólicas.
En la actualidad, la resistencia a la insulina se considera como un tronco común fisiopatológico de algunas enfermedades como la diabetes mellitus, la hipertensión arterial y la obesidad central, además de estar presente en individuos intolerantes a la glucosa o incluso en el 25% de sujetos delgados, aparentemente sanos con tolerancia normal a la glucosa.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.

  2. Mayer B, Davidson MD. Clinical implications of insulin resistance syndromes. Am J Med 1995; 99: 420-426.

  3. Haffner SM, Valdez RA, Hazuda HP. Prospective analysis of the insulin resistance syndrome. Diabetes 1992; 41: 715-722.

  4. Colagiuri S. Brand Miller JC. The metabolic syndrome: from inherited survival trait to health care problem. Exp Clin End Diabetes 1997; 105(suppl 2): 54-60.

  5. Lifshitz A. El estado prediabético. Rev Med IMSS (Méx) 1993; 33: 197-205.

  6. Gulli G, Ferrannini E, Stern S, De Fronzo RA. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two mexican-american NIDDM parents. Diabetes 1992; 41: 1575-1586.

  7. Natali A, Buzzigli G, Taddei S, Santoro D, Cri M et al. Effects of insulin on hemodynamics and metabolism in human forearm. Diabetes 1990; 39: 490-500.

  8. Albert KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. part 1: diagnosis and classification of diabetes mellitus provisional report of a who consultation. Diabetes Med 1998; 15: 539-553.

  9. Sanchez L JJ, Ortiz GC, Rojano MJC et al. Chronic metabolic syndrome: A predictive model of risk of macrovascular events? Aten Primaria 1997; 20(4): 168-172.

  10. Tschoepe D, Roesen P. Heart disease in diabetes mellitus: a challenge for early diagnosis and intervention. Exp Clin Endocrinol Diabetes 1998; 106 (1): 16-24.

  11. Hanefeld M. The metabolic syndrome: Roots, myths, and facts. Hanefeld M, Leonnnardt HW (eds). The metabolic syndrome. Germany: Gustav Fischer, 1997; 13-24.

  12. Hales CN. Metabolic consequences of intrauterine growth retardation. Acta Paediatr 1997; 423 (suppl): 189-197.

  13. Hanefeld M, Temelkova Kurktschiev. The postprandial state and the risk of atherosclerosis. Diabetic Med 1997; 14: S6-S11.

  14. Vallance P, Calver A, Coller J. The vascular endothelium in diabetes and hypertens. J Hypertens 1992; 10 (suppl): 525-529.

  15. Segunda Reunión de Expertos en Dislipidemias organizada por la Asociación Mexicana para la Prevención de la Aterosclerosis y sus Complicaciones, AC. Lineamientos sobre la detección, el manejo diagnóstico y el tratamiento dietario y farmacológico de la hipercolesterolemia y la hipertrigliceridemia. Rev Mex Cardiol 1996; 7 (1):7-24

  16. Vetta F, Cicconetti S, Ronzoni V, Rizzo L. Hyperinsulinemia, regional adipose tissue distribution and left ventricular mass in normotensive, erderly, obese subjects. Eur Heart J 1998; 19:326-331.

  17. Stoll Ba. Impaired ovulation and breast cancer risk. Europ J Cancer 1997; 333 (10): 1532-1535.

  18. Bergman RN. New concepts in extracellular signaling for insulin action: the single gate way hypothesis. Recent Progr Horm Res 1997; 52: 359-385.

  19. McCarty MF. Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: relevance to caloric restriction, exercise and insulin sensitivity. Med Hypothesis 1997; 48 (4): 297-305.

  20. Flack JM. Epidemiologic and clinical aspects of insulin resistance and hiperinsulinemia. Am J Med 1991; (suppl 1A): 115-205.

  21. Mitchell BD, Stern MP, Haffner SM. Risk factors for factors for cardiovascular mortality in mexican americans and non hispanic whites: the San Antonio Heart Study. Am J Epidemiol 1990; 131: 423-433.

  22. Charles MA. Eschwege E. Bennett PH. Non insulin-dependent diabetes in populations at risk: The Pima indians. Diabetes Metabol 1997; 23 (supp 4); 4: 6-9.

  23. Phillips DI. Birth weight and the future development of diabetes. a review of the evidence. Diabetes Care 1998; supp l2: b150-b155.

  24. Barker DJ. The fetal origins of coronary heart disease. Acta Paediatr 1997; 422 (suppl 1): 78-82.

  25. Stern M. Kelly west lecture primary prevention of type 2 diabetes mellitus. Diabetes Care 1991; 14: 399-410.

  26. Kissebah AH. Insulin resistance in visceral obesity. Int J Obes 1991; 15: 109-115.

  27. Hsueh W, Buchanan T. Obesity and hypertension. Endocrinol Clin N Am 1994; 23: 405.

  28. Mino D, Wacher N, Amato D et al. Insulins resistance in offspring of hypertensive subjects. J Hypertension 1996; 14: 1189-1193.

  29. Sane T, Tskinen MR. Does familial hypertriglyceridemia predispose to NIDDM? Diabetes Care 1993; 16: 1494-1501.

  30. Leyva F, Gosland IF, Ghatei M, Proudler AJ et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998; 18 (6): 928-933.

  31. Fernández-Real JM, Ricart-Eugel W, Arroyo E, Balanca R, Casamitjava-Abella R et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21 (1): 62-68.

  32. Preuss HG. Effects of glucose insulin perturbations on aging and chronic disorders of aging: The evidence. J Am Coll Nutr 1997; 16 (5): 397-403.

  33. Catalano PM, Tysbir DE, Roman NM, Amini SB, Sims EAB. Longitudinal changes in insulin release and insulin resistance in non-obese pregnant women. Am J Obstet Gynecol 1991; 165: 1667-1672.

  34. DeFronzo R and Ferranini E. Insulin resistance a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atheroesclerotic cardiovascular disease. Diabetes Care 1991; 14:173-194.

  35. Dinneen SF. The postprandial state: mechanisms of glucose intolerance. Diabetic Med 1997; 14: 519-524.

  36. DeFronzo RA. Insulin resistance and hyperinsulinemia: the link between NIDDM, cad, hypertension and dyslipidemia. In: Schwartz CJ, Bom GV (eds). New horizons in diabetes mellitus and cardiovascular disease. London, UK: Current Science, 1995.

  37. Khan CR. The insulin receptor, insulin action and the mechanisms of insulin resistance in diabetes and atherosclerosis. In: Schwartz CJ, Bom GV (eds). New horizons in diabetes mellitus and cardiovascular disease. London, UK: Current Science 1995.

  38. Ezaki O. Regulatory elements in the insulin-responsive glucose transporter (GLUT 4) gene. Bio Chem Biophy Res Comm 1997; 241 (1): 1-6.

  39. Lieberman J, Sastre A. Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann Intern Med 1980; 93: 825-826.

  40. Torlone E, Rambotti AM, Perriello G et al. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetología 1991; 34: 119-125.

  41. Axelrod L. Insulin, prostaglandins and the pathogenesis of hypertension. Diabetes 1991; 40: 1223-1227.

  42. Haller H. Introduction. The postprandial state: how glucose and lipids may affect atherosclerosis and cardiovascular disease. Diabetic Med 1997; 14: S5.

  43. Oliver FJ, De la Rubia G, Feener EP, Lee ME. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem 1991; 266: 23251-23256.

  44. Hue-M, Levin ER, Pedram A. Insulin stimulates production and secretion of endothelin cells. Diabetes 1993; 42: 351-358.

  45. Scherrer U, Owlya R, Lepori M. Body fat and sympathetic nerve activity. Card Drug Ther 1996; 10: 215-222.

  46. Scherrer V. Sarturi C. Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96 (11): 4104-4113.

  47. Juhlin-Dannfelt A, Frisk-Holmberg F. Central and peripheral circulation in relation to muscle-fibre composition in normo and hypertensive man. Clin Sci 1979; 56: 335-340.

  48. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-420.

  49. Bjorntorp P. Body Fat Distribution, Insulin resistance, and metabolic diseases. Nutrition 1997; 13 (9): 795-803.

  50. Kern PA. Potential role of TNF-alpha and lipoprotein lipase as candidate genes for obesity. J Nutr 1997; 127 (9): 1917S-1922S.

  51. Steiner G. Diabetes and atherosclerosis a lipoprotein perspective. Diabetic Med 1997; 14: S38-S44.

  52. Laakso M, Sarlund H, Mkkänenl. Insulin resistance is associates with lipid and lipoprotein abnormalities in subjects with various degrees of glucose tolerance. Arteriosclerosis 1990; 10: 227-231.

  53. Karpe F. Mechanisms of postprandial hyperlipidaemia- remnants and coronary artery disease. Diabetic Med 1997; 14: S60-S66.

  54. Coppack SW. Postprandial lipoproteins in non-insulin-dependent diabetes mellitus. Diabetic Med 1997; 14: S67-S74.

  55. Facchini F, Chen YD, Hollenbeck CB, Reaven GM: Relationship between resistance to insulin- mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-3011.

  56. Termaaten JC, Voorburg A, Heine RJ, Terwee PM, Donker AJM, Gans ROB. Renal handling of urate and sodium during acute physiological hyperinsulinemia in healthy subjects. Clin Sci 1997; 92: 51-58.

  57. Muscelly E, Natali A, Bianchi S, Bigazzi X, Galvan AQ et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996; 9: 746-752.

  58. Puig JG, Mateos PA, Miranda ME, Torres RJ, Demiguel E et al. Purine metabolism in women with primary gant. Am J Med 1994; 97: 332-338.

  59. Rathmann W. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: The Cardie Study. Coronary artery risk development in young adults. Ann Epidemiology 1998; 8 (4): 250-261.

  60. Meirow D, Yossepowitch O, Rösler A, Brzezinski A, Schenker JG et al. Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Hum Reprod 1995; 10 (8): 1951-1956.

  61. Homburg R, Giudice LC, Chang RJ. Polycystic ovary syndrome. Hum Reprod 1996; 11 (3): 465-466.

  62. Prelevic GM. Insulin resistance in polycystic ovary syndrome. Curr Op Obstet Gynecol 1997; 9 (3): 193-201.

  63. Laughlin-GA, Morales-AJ, Yenn-SS. Serum leptin levels in women with polycystic ovary syndrome: The role of insulin resistance/hyperinsulinemia. J Clin Endocrinol Metab 1997; 82 (6): 1692-1696.

  64. Wild-RA. Metabolic aspects of polycystic ovary syndrome. Sem Reprod Endocrinol 1997; 15 (2): 105-110.

  65. Davison RM. New approaches to insulin resistance in polycystic ovarian syndrome. Curr Opin Obstet Gynecol 1998; 10 (3): 193-198.

  66. Nestler-JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Sem Reprod Endocrinol 1997; 15 (2): 111-122.

  67. Kazer-RR. Lecturing on polycystic ovary syndrome (pcos). Sem Reprod Endocrinol 1997; 15(2): 193-194.

  68. Nestler JE. Insulin regulation of human ovarian androgens. Human Reproduction 1997; (suppl 1): 53-62.

  69. Moller De, Flier JJS. Insulin resistance: Mechanisms, syndromes and implications. N Engl J Med 1991; 325: 938-948.

  70. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81 (4a): 18b-25b.

  71. Despres JP, Larmarche B, Mauriege MSP et al. Hiperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.

  72. Ariza CR, Frati AC, Gomez G, Almazan A: Hyperinsulinemia in patients with coronary heart disease in abscence of overt risk factors. Arch Med Res 1997; 28: 119-155.

  73. American Diabetes Association. Consensus development conference on insulin resistence. Diabetes Care 1998; 21: 310-314.

  74. Scheen AJ. Perspective in the treatment of insulin resistance. Human Reproduction 1997; 12 (suppl 1): 63-71.

  75. Salmeron J, Ascherio A, Rimm EB, Colditz GA, Spiegelman D et al. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 1997; 29: 545-550.

  76. Frati A, Iniestra F, Ariza CR. Acute effect of cigarette smoking on glucose tolerance and other cardiovascular risk factor. Diabetes Care 1996; L 9: 112-118.

  77. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose intolerance. Diabetes Care 1997; 20: 537-544.

  78. Eriksson KF, Lindgärde F, Prevention of type 2 (non-insulin dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991; 34: 891-898.

  79. Arner P, Regulation of lipolysis in fat cells. Diabetes Rev 1996; 4: 450-463.

  80. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (position statement). Diabetes Care 1998; 21: S32-S35.

  81. American Diabetes Association. Consensus development conference on insulin resistance. Diabetes Care 1998; 21: 310-314.

  82. Pafferbarger RS Jr, Hy RT, Wing AL, Lee MI, Jung DL, Kampert JB. The association of changes in physical activity level and other life style characteristic with mortality among men. N Engl J Med 1993; 328: 538-545.

  83. Chaisson JL, Nathan DM, Josse RG et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190.

  84. Bell PM, Hadden DR. Metformin. Endocrinol Metab. Clin North Am 1997; 26: 523-537.

  85. Fontbonne A, Charles MA, Juahan-Vague I, Bard JM, André P, Isnard F et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996; 19: 920-926.

  86. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 1997; 26: 553-573.

  87. Rosenbaum M, Leibel RL. Hirsch. Obesity. N Engl J Med 1997; 337: 396-407.

  88. Durrington PW, Mackness MI, Bhatnagar D, Julier K, Prais H et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998; 138: 217-225.

  89. Farnier M. Cerivastatin in the treatment of mixed hyperlipidemia: The RIGTH study. The Cerivastatin study group. Cerivastatin Gemfibrozil hyperlipidemia treatment. Am J Cardiol 1998; 82 (4B): 47J-51J.

  90. Yee HS, Pong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother 1998; 32 (10): 1030-1043.

  91. Ames RP, Hill P. Elevation of serum lipids during diuretic treatment of hypertension. Am J Med 1976; 61: 748-752.

  92. Lithell HO, Weiner L, Selinus I, Vessby B. A comparison of the effects of Bisoprolol and aterolol on lipoprotein concentrations and blood pressure. J Cardiovasc Pharmacol 1986; 13: (8): 5128-5133.

  93. Schneider M, Lerch M, Papiri M, Buchel P, Bohlen L et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1996; 14: 669-677.

  94. Murphy MB, Lewis PJ, Kohner E, Shummer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics: a 14 year follow-up. Lancet 1982; 2: 1293-1295.

  95. Janka HV, Weitz TH, Blümmer, Van Michel A, Mehnert H. Hypertension and microalbuminuria in diabetic patients taking indapamide. J Hypertens 1989; 7 (suppl 6): 5316-5317.

  96. Miettinen TA, Vanhaven H, Huttunen JK, Naukkarinen V. Mattila S et al. HDL cholesterol and beta-adrenoceptor blocking agents in a year multifactorial primary prevention trial. Br J Clin Pharmacol 1982; 13: 431-445.

  97. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidn Int 1992, 41: 912-919.

  98. Parving HA. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertension 1990; 8: 5187-5191.

  99. Bohlen L, De Courten M, Weidmann P. Comparative study of the effect of ace-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7 (suppl): 39-45.

  100. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment of insulin sensitivity with special reference to ace inhibitors. Diabetes Care 1991; 14 (suppl 4): 39-47.

  101. The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. USA: National Institutes of Health No. 98 - 4080, 1997: 47-50.

  102. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-887.

  103. Dzav VJ. Atherosclerosis and Hypertension: Mechanisms and interrelationships. J Cardiovasc Pharmacol 1990; 15 (S5): S59-S64.

  104. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16 (4): 621-629.

  105. Vazquez EM, Mendoza S, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43 (5): 647-654.

  106. Nestler JE, Jakubowics. Decreases in ovarian cytochrome p450c17 (alpha) activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617-623.

  107. Jean-Louis Chiason. Concepts for primary prevention of non-insulin-dependent diabetes mellitus. In: Hanefeld M, Leonnnardt HW (eds). The metabolic syndrome. Gustav Fischer 1997: 133-139.

  108. Eckel RH. Insulin Resistance: an adaptation for weight maintenance. Lancet 1992; 340: 1452-1453.




2020     |     www.medigraphic.com